Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | GAA | P10253 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL68768 | 1.00 | KDM4E (0.34) | KDM4EALDH1A1SMN1; SMN2AKR1C3MEN1 | |
| SCHEMBL3699476 | 0.88 | AKR1C3 (0.43) | KDM4EALDH1A1SMN1; SMN2AKR1C3MEN1 | |
| SCHEMBL3699477 | 0.88 | AKR1C3 (0.43) | KDM4EALDH1A1SMN1; SMN2AKR1C3MEN1 | |
| SCHEMBL68766 | 0.86 | FDPS (0.42) | KDM4EALDH1A1SMN1; SMN2AKR1C3GAA | |
| SCHEMBL4361050 | 0.84 | KDM4E (0.38) | KDM4EALDH1A1SMN1; SMN2AKR1C3 | |
| SCHEMBL4361055 | 0.84 | KDM4E (0.38) | KDM4EALDH1A1SMN1; SMN2AKR1C3 | |
| SCHEMBL1400796 | 0.83 | PDK2 (0.32) | KDM4EAKR1C3 | |
| SCHEMBL1400797 | 0.83 | PDK2 (0.32) | KDM4EAKR1C3 | |
| SCHEMBL3698882 | 0.82 | RXRA (0.40) | AKR1C3 | |
| SCHEMBL68525 | 0.80 | PTGER1 (0.33) | KDM4EALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8129416-B2 | Biaromatic compounds that modulate PPARgamma type receptors and cosmetic/pharmaceutical compositions comprised thereof | GALDERMA RESEARCH & DEVELOPMENT (FR) | 2012-03-06 | — | — | US | disclosed |
| EP-1814871-B1 | COMPOUNDS THAT MODULATE PPARY TYPE RECEPTORS, AND USE THEREOF IN COSMETIC OR PHARMACEUTICAL COMPOSITIONS | GALDERMA RES & DEV (FR) | 2011-03-02 | — | — | EP | disclosed |
| US-20080027077-A1 | Novel biaromatic compounds that modulate PPARgamma type receptors and cosmetic/pharmaceutical compositions comprised thereof | GALDERMA RESEARCH & DEVELOPMENT (FR) | 2008-01-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080027077-A1 | Novel biaromatic compounds that modulate PPARgamma type receptors and cosmetic/pharmaceutical compositions comprised thereof | PPARG, PPARD, PPARA | KDM4E 4032/4885ALDH1A1 624/4885SMN1; SMN2 4797/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.